Compare NNNN & CAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | CAF |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.2M | 333.7M |
| IPO Year | 2023 | N/A |
| Metric | NNNN | CAF |
|---|---|---|
| Price | $7.90 | $18.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 99.2K | 16.7K |
| Earning Date | 04-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.61 | $14.90 |
| 52 Week High | $51.33 | $21.41 |
| Indicator | NNNN | CAF |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 37.81 |
| Support Level | N/A | $17.81 |
| Resistance Level | $13.01 | $20.26 |
| Average True Range (ATR) | 1.67 | 0.25 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 18.56 | 17.10 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.